Imagine a microscopic invader that quietly settles inside the human brain and can even hijack the very immune cells meant to destroy it. This is the reality for Toxoplasma gondii, a parasite that silently resides in roughly one‑third of the global population.
How the Parasite Enters the Body
People usually encounter Toxoplasma through contact with cat feces, consumption of undercooked meat, or eating produce that has been contaminated. Once inside, the organism spreads via the bloodstream, eventually reaching the brain where it can persist for a lifetime without causing obvious disease in most hosts.
The Unexpected Target: CD8⁺ T Cells
Researchers at the University of Virginia, led by Dr. Tajie Harris, asked a surprising question: can the parasite infect CD8⁺ T cells, the immune soldiers that normally hunt down infected cells? Their experiments revealed that Toxoplasma does indeed invade these T cells, and the infection pushes the cells toward a programmed death.
Caspase‑8: The Cellular Suicide Switch
The team identified the enzyme caspase‑8 as the critical factor that decides the fate of an infected T cell. When caspase‑8 is active, it initiates apoptosis, effectively sacrificing the host cell and eliminating the parasite’s safe haven.
In mouse models lacking caspase‑8 specifically in CD8⁺ T cells, researchers observed dramatically higher parasite loads in the brain. Those mice became severely ill and died, whereas control mice with functional caspase‑8 remained healthy despite mounting strong immune responses.
Why This Matters
The findings highlight a previously underappreciated defense mechanism: the self‑destruction of infected T cells prevents Toxoplasma from establishing a long‑term foothold in the brain. This insight could inform new therapeutic strategies for people with weakened immune systems, who are most vulnerable to severe toxoplasmosis.
Study Publication and Funding
The research was published in Science Advances and involved a multidisciplinary team from UVA’s Center for Brain Immunology and Glia. Funding sources included multiple NIH grants, a UVA Pinn Scholars Award, and the university’s Strategic Investment Fund.